Your browser is no longer supported. Please, upgrade your browser.
Settings
REXN Rexahn Pharmaceuticals, Inc. daily Stock Chart
REXN [NASD]
Rexahn Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own0.31% Shs Outstand4.48M Perf Week-1.40%
Market Cap9.43M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.22M Perf Month0.95%
Income-6.90M PEG- EPS next Q- Inst Own8.30% Short Float0.32% Perf Quarter-24.29%
Sales1.20M P/S7.86 EPS this Y58.40% Inst Trans-30.23% Short Ratio0.24 Perf Half Y11.52%
Book/sh1.74 P/B1.22 EPS next Y- ROA-55.70% Target Price- Perf Year29.27%
Cash/sh2.07 P/C1.03 EPS next 5Y- ROE-72.60% 52W Range1.26 - 4.26 Perf YTD10.99%
Dividend- P/FCF- EPS past 5Y29.60% ROI- 52W High-47.18% Beta1.12
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin- 52W Low78.20% ATR0.15
Employees5 Current Ratio3.40 Sales Q/Q- Oper. Margin- RSI (14)56.23 Volatility5.58% 6.27%
OptionableNo Debt/Eq0.00 EPS Q/Q-1.90% Profit Margin- Rel Volume0.66 Prev Close2.12
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume57.67K Price2.25
Recom3.00 SMA205.14% SMA505.47% SMA200-2.01% Volume33,572 Change6.13%
Aug-08-19Downgrade IFS Securities Outperform → Market Perform
Oct-15-20 04:23PM  
Aug-22-20 07:35AM  
Aug-21-20 09:28PM  
Aug-09-20 07:01AM  
Aug-07-20 10:22PM  
Jul-25-20 12:10PM  
Jul-24-20 09:21PM  
Jul-22-20 05:10PM  
Jul-21-20 12:36PM  
Jul-18-20 11:15AM  
Jul-17-20 03:15PM  
Jul-15-20 06:48PM  
03:35PM  
Jul-14-20 11:30AM  
Jul-10-20 12:00PM  
Jul-08-20 06:00PM  
Jul-07-20 09:07PM  
07:44PM  
Jul-03-20 02:50AM  
Jul-01-20 06:53PM  
Jun-29-20 04:47PM  
Jun-26-20 09:03PM  
Jun-17-20 11:30PM  
Apr-08-20 12:32PM  
Sep-24-19 06:57PM  
06:50AM  
Sep-02-19 09:17AM  
Aug-07-19 06:30AM  
Jul-11-19 03:45PM  
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.